<DOC>
	<DOCNO>NCT02628717</DOCNO>
	<brief_summary>Since availability interferon free direct acting antiviral ( DAA ) center authorize prescribed drug Austria submit data central data base ( AURIC ) use treatment regime without interferon ribavirin patient advance liver disease ( F3/4 )</brief_summary>
	<brief_title>Interferon/Ribavirin-Free Sofosbuvir Based Treatment ( AURIC )</brief_title>
	<detailed_description>From end 2013 303 HCV-monoinfected patient advance liver disease ( F3/4 ) treat interferon ( IFN ) -free RBV-free SOF-based regimen . During period 7 patient receive additional RBV . These patient include analysis . Only patient complete 12 week treatment-free follow July 2015 include analysis . In Austria , prescription DAAs restrict specialized treatment center . Data obtain 6 participate center submit central database form Austrian Ribavirin- Interferon-free cohort ( AURIC ) . Incoming data review staff hepatitis study group Dept . Medicine III , Medical university Vienna.The treatment regimen consist SOF/DCV , SOF/SMV , SOF/LDV . The duration treatment base response guide approach discretion treat physician ( 12 24 week ) . Sixty six patient start therapy August 2014 receive SMV DCV part name patient program , SOF prescribe . For remain patient drug prescribe pay Austrian social insurance . This study investigate various aspect treatment response regimens contain direct-acting antiviral agent treatment chronic hepatitis C : Sustained virologic response ( SVR ) define undetectable HCV-RNA 12 week treatment free follow Virological breakthrough/relapse define reappearance HCV treatment/during follow Impact viral kinetics prediction treatment efficacy : Viral load measure repeatedly ( baseline , day 2,7,14,21,28 , every 4 week end treatment ) allow study rapidity viral clearance . This parameter use ass whether length treatment modify . Plasma HCV RNA level quantify One Signal Amplification ( Versant HCV RNA 3.0 ) , Adverse Event Recording ( use standard GCP criterion ) Longterm outcome SVR base examine patient SVR six monh interval . Examination include liver sonography , elastography , routine blood chemistry include alpha1-fetoprotein</detailed_description>
	<mesh_term>Hepatitis</mesh_term>
	<mesh_term>Hepatitis C</mesh_term>
	<mesh_term>Hepatitis , Chronic</mesh_term>
	<mesh_term>Hepatitis C , Chronic</mesh_term>
	<mesh_term>Interferons</mesh_term>
	<mesh_term>Ribavirin</mesh_term>
	<mesh_term>Sofosbuvir</mesh_term>
	<criteria>All adult patient ( age 18 old ) treat antiviral HCV treatment regimens disease poor prognosis ( ie . metastatic cancer , heart failure ) participation clinical trial</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>Hepatitis C</keyword>
	<keyword>sofosbuvir</keyword>
	<keyword>ledipasvir</keyword>
	<keyword>daclatasvir</keyword>
	<keyword>simeprevir</keyword>
</DOC>